Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress June 7, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited final results for the 12 months ended 31 December 2021. Financial highlights · Record revenues of £39.0m (2020: £22.2m) achieved representing 76% growth · £9m improvement in EBITDA generating £2.9m (2020: £(6.1)m) · Cash and cash equivalents as at 31 December 2021 of £15.7m…

Open Orphan #ORPH – £7.3m Influenza human challenge study contract win May 18, 2022 – Posted in: Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.3m influenza human challenge study (“Study”) contract with a leading biotechnology company to test its antiviral product using the hVIVO Influenza Human Challenge Study Model. The randomised, double-blinded, placebo-controlled study will test and assess the antiviral prophylactic and…

Open Orphan #ORPH – COVID-19 Characterisation Study peer reviewed results published in industry leading periodical Nature Medicine March 31, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the results from the world’s first COVID-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. ‘Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge’ by Killingley, B. et al. is available in Nature Medicine, https://www.nature.com/articles/s41591-022-01780-9 DOI: 10.1038/s41591-022-01780-9 The study, which was…

Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress June 7, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – £7.3m Influenza human challenge study contract win May 18, 2022 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH – COVID-19 Characterisation Study peer reviewed results published in industry leading periodical Nature Medicine March 31, 2022 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL